USANA Health Sciences (NYSE:USNA) updated its FY 2022 earnings guidance on Tuesday. The company provided EPS guidance of $5.250-$6.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.780. The company issued revenue guidance of $1.13 billion-$1.23 billion, compared to the consensus revenue estimate of $1.17 billion.

Several equities analysts have recently commented on the stock. StockNews.com lowered shares of USANA Health Sciences from a strong-buy rating to a buy rating in a research report on Friday. Zacks Investment Research lowered shares of USANA Health Sciences from a strong-buy rating to a hold rating in a research report on Wednesday, December 29th. Finally, TheStreet lowered shares of USANA Health Sciences from a b rating to a c+ rating in a research report on Wednesday, February 9th.

Shares of USNA opened at $89.28 on Tuesday. The firm has a 50-day moving average price of $98.39 and a 200 day moving average price of $97.40. The firm has a market capitalization of $1.74 billion, a PE ratio of 13.63 and a beta of 0.85. USANA Health Sciences has a 52-week low of $79.92 and a 52-week high of $107.85.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Monday, February 7th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.28 by ($0.25). USANA Health Sciences had a net margin of 11.05% and a return on equity of 32.68%. During the same quarter in the prior year, the business posted $1.87 earnings per share. As a group, research analysts anticipate that USANA Health Sciences will post 5.98 earnings per share for the current fiscal year.

In other USANA Health Sciences news, insider Daniel A. Macuga sold 368 shares of the company’s stock in a transaction dated Wednesday, December 8th. The shares were sold at an average price of $100.86, for a total transaction of $37,116.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Walter Noot sold 6,193 shares of the company’s stock in a transaction dated Thursday, December 16th. The shares were sold at an average price of $102.25, for a total transaction of $633,234.25. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in USANA Health Sciences stock. Bank of New York Mellon Corp increased its position in USANA Health Sciences, Inc. (NYSE:USNA) by 1.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 132,542 shares of the company’s stock after buying an additional 1,769 shares during the period. Bank of New York Mellon Corp owned 0.68% of USANA Health Sciences worth $12,220,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.82% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

See Also